Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real World Treatment Patterns, Clinical Outcomes and EGFR / T790M Testing Practices in EGFR-Mutated Advanced Non-Small Cell Lung Cancer Patients Receiving First-Line TKI Therapy

Next Previous
X
Search
Trial Profile

Real World Treatment Patterns, Clinical Outcomes and EGFR / T790M Testing Practices in EGFR-Mutated Advanced Non-Small Cell Lung Cancer Patients Receiving First-Line TKI Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary) ; Antineoplastics
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms REFLECT
  • Sponsors AstraZeneca

    • Most Recent Events

    • 21 Sep 2021 Results of pooled data from Central Eastern Europe (CEE) assessing EGFR/T790M testing and treatment patterns in EGFRm non-small cell lung cancer patients receiving 1G/2G EGFR TKis, presented at the 46th European Society for Medical Oncology Congress.
    • 09 Oct 2020 New trial record
    • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top